THORLNC: A Potential Drug Target and Biomarker (G100506797)

Target Name: THORLNC

NCBI ID: G100506797

THORLNC

Other Name(s): Testis-associated highly-conserved oncogenic long non-coding RNA | THOR | testis associated oncogenic lncRNA | Testis associated oncogenic lncRNA

THORLNC: A Potential Drug Target and Biomarker

THORLNC is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and potentially, develop new treatments.

THORLNC is a microRNA (miRNA), which is a small RNA molecule that plays a crucial role in post-transcriptional gene regulation. MiRNAs are made from a hairless region of DNA and have the ability to interact with mRNAs to either activate or repress their translation into proteins. This interaction between miRNAs and mRNAs is critical for gene expression and can be regulated by various factors, including changes in the levels of miRNA and mRNA.

Studies have shown that THORLNC is involved in various cellular processes, including cell growth, apoptosis, and metabolism. It has been shown to play a role in the regulation of cell cycle progression, and has been linked to the G1/S transition, which is the critical step in the cell cycle where DNA replication and protein synthesis occur. Additionally, THORLNC has been shown to be involved in the regulation of apoptosis, which is the natural process of cell death that occurs when a cell reaches its genetic limit and undergoes programmed cell death.

In neurodegenerative diseases, THORLNC has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the maintenance of neuronal structure and function. This suggests that THORLNC may be a potential target for neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

In addition to its role in neurodegenerative diseases, THORLNC has also been shown to be involved in the regulation of cancer cell growth and metabolism. This suggests that it may be a potential target for cancer therapies that target these processes.

The discovery and characterization of THORLNC as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Testis Associated Oncogenic LncRNA

The "THORLNC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about THORLNC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets